Angiodynamics Inc (ANGO)

$5.87

-0.16

(-2.65%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Angiodynamics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 79.07M → 75.18M (in $), with an average decrease of 4.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 45.88M → -187.73M (in $), with an average decrease of 354.8% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 27.8% return, outperforming this stock by 57.4%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 29.2% return, outperforming this stock by 105.1%

Performance

  • $5.83
    $6.02
    $5.87
    downward going graph

    0.68%

    Downside

    Day's Volatility :3.16%

    Upside

    2.49%

    downward going graph
  • $5.27
    $11.38
    $5.87
    downward going graph

    10.22%

    Downside

    52 Weeks Volatility :53.69%

    Upside

    48.42%

    downward going graph

Returns

PeriodAngiodynamics IncSector (Health Care)Index (Russel 2000)
3 Months
-0.82%
2.0%
0.0%
6 Months
-6.66%
11.7%
0.0%
1 Year
-29.56%
5.8%
1.3%
3 Years
-76.0%
14.2%
-22.1%

Highlights

Market Capitalization
250.7M
Book Value
$5.41
Earnings Per Share (EPS)
-4.8
PEG Ratio
1.87
Wall Street Target Price
13.5
Profit Margin
-59.37%
Operating Margin TTM
-19.28%
Return On Assets TTM
-4.81%
Return On Equity TTM
-62.42%
Revenue TTM
324.0M
Revenue Per Share TTM
8.11
Quarterly Revenue Growth YOY
-6.9%
Gross Profit TTM
174.2M
EBITDA
-4.9M
Diluted Eps TTM
-4.8
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.52
EPS Estimate Next Year
-0.49
EPS Estimate Current Quarter
-0.13
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Angiodynamics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
7
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 129.98%

Current $5.87
Target $13.50

Company Financials

FY18Y/Y Change
Revenue
344.3M
↓ 1.53%
Net Income
16.3M
↑ 133.09%
Net Profit Margin
4.74%
↑ 2.74%
FY19Y/Y Change
Revenue
359.5M
↑ 4.41%
Net Income
61.3M
↑ 275.51%
Net Profit Margin
17.06%
↑ 12.32%
FY20Y/Y Change
Revenue
264.2M
↓ 26.52%
Net Income
-165.8M
↓ 370.28%
Net Profit Margin
-62.76%
↓ 79.82%
FY21Y/Y Change
Revenue
291.0M
↑ 10.17%
Net Income
-31.5M
↓ 80.97%
Net Profit Margin
-10.84%
↑ 51.92%
FY22Y/Y Change
Revenue
316.2M
↑ 8.66%
Net Income
-26.5M
↓ 15.85%
Net Profit Margin
-8.4%
↑ 2.44%
FY23Y/Y Change
Revenue
338.8M
↑ 7.13%
Net Income
-52.4M
↑ 97.54%
Net Profit Margin
-15.48%
↓ 7.08%
Q4 FY22Q/Q Change
Revenue
85.4M
↑ 4.77%
Net Income
-8.5M
↓ 34.74%
Net Profit Margin
-9.93%
↑ 6.02%
Q1 FY23Q/Q Change
Revenue
80.7M
↓ 5.52%
Net Income
-9.5M
↑ 11.77%
Net Profit Margin
-11.75%
↓ 1.82%
Q2 FY23Q/Q Change
Revenue
91.1M
↑ 12.84%
Net Income
-21.5M
↑ 126.33%
Net Profit Margin
-23.57%
↓ 11.82%
Q3 FY23Q/Q Change
Revenue
78.7M
↓ 13.61%
Net Income
45.9M
↓ 313.74%
Net Profit Margin
58.32%
↑ 81.89%
Q4 FY23Q/Q Change
Revenue
79.1M
↑ 0.5%
Net Income
-29.0M
↓ 163.31%
Net Profit Margin
-36.74%
↓ 95.06%
Q1 FY24Q/Q Change
Revenue
75.2M
↓ 4.92%
Net Income
-187.7M
↑ 546.3%
Net Profit Margin
-249.71%
↓ 212.97%
FY18Y/Y Change
Total Assets
705.5M
↓ 0.35%
Total Liabilities
162.9M
↓ 14.69%
FY19Y/Y Change
Total Assets
836.4M
↑ 18.56%
Total Liabilities
221.6M
↑ 36.07%
FY20Y/Y Change
Total Assets
595.5M
↓ 28.8%
Total Liabilities
139.6M
↓ 36.99%
FY21Y/Y Change
Total Assets
561.4M
↓ 5.72%
Total Liabilities
122.0M
↓ 12.65%
FY22Y/Y Change
Total Assets
552.8M
↓ 1.55%
Total Liabilities
128.3M
↑ 5.15%
FY23Y/Y Change
Total Assets
532.6M
↓ 3.64%
Total Liabilities
154.3M
↑ 20.33%
Q4 FY22Q/Q Change
Total Assets
558.2M
↑ 0.1%
Total Liabilities
150.2M
↑ 4.62%
Q1 FY23Q/Q Change
Total Assets
542.8M
↓ 2.75%
Total Liabilities
145.2M
↓ 3.36%
Q2 FY23Q/Q Change
Total Assets
532.6M
↓ 1.88%
Total Liabilities
154.3M
↑ 6.3%
Q3 FY23Q/Q Change
Total Assets
493.9M
↓ 7.26%
Total Liabilities
66.1M
↓ 57.14%
Q4 FY23Q/Q Change
Total Assets
499.6M
↑ 1.15%
Total Liabilities
98.4M
↑ 48.76%
Q1 FY24Q/Q Change
Total Assets
324.8M
↓ 34.98%
Total Liabilities
106.1M
↑ 7.87%
FY18Y/Y Change
Operating Cash Flow
41.3M
↓ 25.94%
Investing Cash Flow
-3.7M
↑ 43.32%
Financing Cash Flow
-11.6M
↓ 69.59%
FY19Y/Y Change
Operating Cash Flow
37.4M
↓ 9.32%
Investing Cash Flow
82.6M
↓ 2358.04%
Financing Cash Flow
33.9M
↓ 393.75%
FY20Y/Y Change
Operating Cash Flow
-14.6M
↓ 138.87%
Investing Cash Flow
-63.3M
↓ 176.73%
Financing Cash Flow
-95.2M
↓ 380.69%
FY21Y/Y Change
Operating Cash Flow
24.1M
↓ 265.54%
Investing Cash Flow
-13.7M
↓ 78.36%
Financing Cash Flow
-17.0M
↓ 82.17%
FY22Y/Y Change
Operating Cash Flow
-7.2M
↓ 129.86%
Investing Cash Flow
-19.3M
↑ 40.81%
Financing Cash Flow
7.7M
↓ 145.23%
FY23Y/Y Change
Operating Cash Flow
78.0K
↓ 101.08%
Investing Cash Flow
-9.7M
↓ 49.52%
Financing Cash Flow
25.4M
↑ 230.86%
Q4 FY22Q/Q Change
Operating Cash Flow
7.5M
↓ 130.31%
Investing Cash Flow
-2.5M
↓ 30.2%
Financing Cash Flow
103.0K
↓ 99.58%
Q1 FY23Q/Q Change
Operating Cash Flow
1.4M
↓ 81.73%
Investing Cash Flow
-2.1M
↓ 14.02%
Financing Cash Flow
941.0K
↑ 813.59%
Q2 FY23Q/Q Change
Operating Cash Flow
16.0M
↑ 1064.53%
Investing Cash Flow
98.4M
↓ 4687.23%
Financing Cash Flow
-180.0M
↓ 19228.59%
Q3 FY23Q/Q Change
Operating Cash Flow
-25.9M
↓ 262.34%
Investing Cash Flow
98.4M
↑ 0.0%
Financing Cash Flow
-59.6M
↓ 66.89%

Technicals Summary

Sell

Neutral

Buy

Angiodynamics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Angiodynamics Inc
Angiodynamics Inc
14.42%
-6.66%
-29.56%
-76.0%
-70.38%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-3.73%
35.94%
25.5%
30.64%
122.62%
Resmed Inc.
Resmed Inc.
-4.7%
31.12%
-18.71%
-12.65%
80.17%
Becton, Dickinson And Company
Becton, Dickinson And Company
-3.02%
-9.59%
-10.56%
-8.97%
0.8%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
0.47%
5.54%
4.9%
21.03%
238.69%
Alcon Ag
Alcon Ag
-2.66%
13.89%
12.29%
6.08%
39.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Angiodynamics Inc
Angiodynamics Inc
41.4
NA
1.87
-0.52
-0.62
-0.05
NA
5.41
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
66.71
66.71
7.13
6.27
0.16
0.08
NA
39.37
Resmed Inc.
Resmed Inc.
29.86
29.86
1.75
7.4
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
53.77
53.77
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
47.63
47.63
6.72
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
41.13
41.13
4.59
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Angiodynamics Inc
Angiodynamics Inc
Buy
$250.7M
-70.38%
41.4
-59.37%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$130.9B
122.62%
66.71
27.16%
Resmed Inc.
Resmed Inc.
Buy
$26.5B
80.17%
29.86
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.6B
0.8%
53.77
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$27.5B
238.69%
47.63
20.12%
Alcon Ag
Alcon Ag
Buy
$39.8B
39.53%
41.13
10.3%

Institutional Holdings

  • BlackRock Inc

    12.66%

  • Vanguard Group Inc

    5.69%

  • Systematic Financial Management LP

    4.85%

  • Morgan Stanley - Brokerage Accounts

    4.73%

  • Millennium Management LLC

    4.61%

  • Dimensional Fund Advisors, Inc.

    3.74%

Company Information

founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie

Organization
Angiodynamics Inc
Employees
815
CEO
Mr. James C. Clemmer
Industry
Health Technology

Discover More

FAQs